High Technology Hospital MedCenter Ltd

Batumi, Adjara 6010

0 studies enrolling now · 3 studies all time

What they study most

Bladder Cancer, Breast Cancer, Chemotherapy-induced Neutropenia, Metastatic Bladder Cancer, Myelosuppression Adult, Non-small Cell Lung Cancer, TNBC - Triple-Negative Breast Cancer, Urothelial Carcinoma

Studies at this site

• Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab — Stopped early
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) — Completed
• Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) — Status unconfirmed